HemoCath-guided healthcare for patients with heart failure has the potential to improve clinical outcomes and reduce hospital length of stay. HemoCath Ltd. is an early-stage Canadian/US/Irish company that has developed and is now commercializing outside the United States the HemoCath Pulmonary Artery (PA) Catheter, indicated for the assessment of a patient’s hemodynamic condition through direct simultaneous central venous pressure (CVP) and pulmonary artery pressure (PAP) monitoring. HemoCath PA Catheter is less invasive due to its 4F catheter size and easier-to-use by design.